Medical Pharmacology: Immunopharmacology (Immunosuppressant/Immunomodulator) Practice Questions
Siponimod (Mayzent)
Click on the correct answer.
Siponimod (Mayzent):
Relatively new oral drug targeting secondary progressive multiple sclerosis (SPMS).
Mechanism of action involves binding to sphingosine-1-phosphate receptors associated with lymphocytes and related cells.
Both
Neither
Siponimod (Mayzent) clinical use/uses:
Relapsing-remitting multiple sclerosis
Active secondary progressive multiple sclerosis
in adults.
Both
Neither
Relapsing-remitting multiple sclerosis (RRMS) is often associated with subsequent period of worsening neurological function, occurring independently of relapse. This phenomenon is described as secondary progressive MS (SPMS).
True
False
Relapsing-remitting MS (RRMS):
Likely driven by peripherally mediated inflammation
Likely associated with chronic central nervous system
(CNS) inflammation and neurodegeneration.
Both
Neither
Siponimod (Mayzent):
Orally active
Modulator at both sphingosine-1-phosphate Type 1 and 5 receptors
Both
Neither
Prior to first dose of siponimod administration:
CYP2C9 genotype assessment
ECG for the purpose of identifying preexisting cardiac conduction abnormalities.
Both
Neither
Siponimod and the heart:
Initial siponimod administration is likely to be associated with the reduction in heart rate.
A first-dose siponimod 6 hour monitoring period is appropriate for patients with existing sinus bradycardia (<55 BPM), 1st or 2nd degree AV block, myocardial infarction history, or heart failure.
Rothlin C Gutkind J Chapter 39
Immunosuppressants, Immunomodulation and Tolerance In
Goodman & Gilman's The Pharmacological Basis of Therapeutics
(Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
Lake D & Briggs A Ch 55 Immunopharmacology
in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed)
16e McGraw Hill 2023.
Gold, R., Piani-Meier, D., Kappos, L. et
al. Siponimod vs placebo in active secondary progressive
multiple sclerosis: a post hoc analysis from the phase 3
EXPAND study. J Neurol 269, 5093–5104 (2022).
https://link.springer.com/article/10.1007/s00415-022-11166-z
Chrouos G Ch 39 Adrenocorticosteroids &
Adrenocortical Antagonists in Katzung's Basic & Clinical
Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
Brezinski E Klickstein L Armstrong A Ch 46
Pharmacology of Immunosuppression in Principles of
Pharmacology: The Pathophysiologic Basis of Drug Therapy.
(Golan DE Armstrong EJ Armstrong AW, eds) 4e 2017 ls) 4e
2017
Ritter JM Flower R Henderson G Loke YK
MacEwan D Robinson E Fullerton J Ch 54 Anti-inflammatory and
Immunosuppressant Drugs Rang & Dale's Pharmacology 10e
Elsevier 2024.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
Burchum J Rosenthal L Lehne's Pharmacology
for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine
Disorders Elsevier 2022.
Bass A Rogatsky Ch 32 Immunomodulatory Drugs
in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier
26e 2020
Leiva M Takemoto Ch 238 Immunosuppressants in
Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et
al, eds) Wolters Kluwer 2023.
Hall J Hall M Ch 78 Adrenocortical
Hormones Guyton and Hall Textbook of Medical Physiology 14e
Elsevier 2021.
